Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): Safety and tolerability

Hypertension Research

Volumn 38, Issue 2, 2015, Pages 132-136

  Saruta, Takao ^a   Ogihara, Toshio ^b   Saito, Ikuo ^a   Rakugi, Hiromi ^c   Shimamoto, Kazuaki ^d   Matsuoka, Hiroaki ^e   Teramukai, Satoshi ^f   Higaki, Jitsuo ^g   Ito, Sadayoshi ^h   Shimada, Kazuyuki ⁱ  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Shin Oyama City Hospital   (Japan)

Author keywords

adverse event; combination therapy; discontinuation; elderly hypertensive patient; olmesartan

Indexed keywords

AMLODIPINE; AZELNIDIPINE; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; OLMESARTAN; POTASSIUM; SODIUM; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TRICHLORMETHIAZIDE; URIC ACID; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FRACTURE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MORBIDITY; OPEN STUDY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENESCENCE; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; DRUG COMBINATION; FEMALE; MALE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84922386826     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.141     Document Type: Article

References (20)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizillbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
3. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochrolothiazide for hypertension in high-risk patients. N Engl J Med 2008; 369: 2417-2428.
4. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 42-50.
5. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649-1659.
6. Agarwal R, Weir MR. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. J Hypertens 2013; 31: 1692-1701.
7. Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35: 441-448.
8. Ohishi M, Kawai T, Hayashi N, Kitano S, Katsuya T, Nagano M, Hirotani A, Yamamoto K, Kamide K, Rakugi H. Effect of tablets with a combination of telmisartan and amlodipine on patients with hypertension: the Cotalo study. Hypertens Res 2013; 36: 620-626.
9. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahahi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S. for the COLM Investigators Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens 2014; 32: 2054-2063.
10. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki I, Katayama S, Saito I, Shimada K, on behalf of the COLM study investigators. Rationale, study design and implementation of the COLM study: the combination of olmesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32: 163-167.
11. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129-1133.
12. La Croix AZ, Ott SM, Ichikawa L, Scoles D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in order adults. Ann Intern Med 2000; 133: 516-526.
13. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335.
14. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
15. Saruta T, Ogihara T, Matsuoka H, Suzuki H, Toki M, Hirayama Y, Nonaka K, Takahashi K. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729-739.
16. Franse LV, Pahor M, Bari MD, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1154.
17. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Trial Collaborative Group. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069-1074.
18. Holeggens A, Alderman MH, Kjeldsen S, Julius S, Devereua RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B, for the LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
19. Ito S, Naritomi H, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertens Res 2012; 35: 867-873.
20. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326: 1427-1431.